



Published in final edited form as:

*Clin Cancer Res.* 2013 June 1; 19(11): 2929–2940. doi:10.1158/1078-0432.CCR-12-2307.

## Development of a Colon Cancer GEMM-Derived Orthotopic Transplant Model for Drug Discovery and Validation

Eric S. Martin<sup>a,§,\*</sup>, Peter J. Belmont<sup>b,\*</sup>, Mark J. Sinnamon<sup>c,\*</sup>, Larissa Georgeon Richard<sup>c,\*</sup>, Jing Yuan<sup>b</sup>, Erin M. Coffee<sup>c</sup>, Jatin Roper<sup>c</sup>, Lydia Lee<sup>c</sup>, Pedram Heidari<sup>d</sup>, Sophia Y. Lunt<sup>e</sup>, Gautam Goel<sup>f</sup>, Christy Ji<sup>b</sup>, Julie Xie<sup>b</sup>, Tao Xie<sup>b</sup>, John Lamb<sup>b</sup>, Scott Weinrich<sup>b</sup>, Todd VanArsdale<sup>b</sup>, Roderick T. Bronson<sup>g</sup>, Ramnik J. Xavier<sup>f</sup>, Matthew G. Vander Heiden<sup>e</sup>, Julie L. C. Kan<sup>b</sup>, Umar Mahmood<sup>d</sup>, and Kenneth E. Hung<sup>c,§</sup>

<sup>a</sup>Dana-Farber Cancer Institute, Boston, MA 02115; Current Address: Oncology Research Unit, Pfizer Global Research and Development, San Diego, CA 92121

<sup>b</sup>Oncology Research Unit, Pfizer Global Research and Development, San Diego, CA 92121

<sup>c</sup>Division of Gastroenterology, Tufts Medical Center, Boston, MA 02111

<sup>d</sup>Department of Radiology, Massachusetts General Hospital, Boston, MA 02115

<sup>e</sup>Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Boston, MA 02115

<sup>f</sup>Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA 02115

<sup>g</sup>Dana-Farber Cancer Institute, Boston, MA 02115

### Abstract

**Purpose**—Effective therapies for *KRAS* mutant colorectal cancer (CRC) are a critical unmet clinical need. Previously, we described GEMMs for sporadic *Kras* mutant and non-mutant CRC suitable for preclinical evaluation of experimental therapeutics. To accelerate drug discovery and validation, we sought to derive low-passage cell lines from GEMM *Kras* mutant and wild-type tumors for *in vitro* screening and transplantation into the native colonic environment of immunocompetent mice for *in vivo* validation.

**Experimental Design**—Cell lines were derived from *Kras* mutant and non-mutant GEMM tumors under defined media conditions. Growth kinetics, phosphoproteomes, transcriptomes, drug sensitivity, and metabolism were examined. Cell lines were implanted in mice and monitored for *in vivo* tumor analysis.

**Results**—*Kras* mutant cell lines displayed increased proliferation, MAPK signaling, and PI3K signaling. Microarray analysis identified significant overlap with human CRC-related gene

§Correspondence: Eric.Martin@pfizer.com, kenneth.e.hung@gmail.com.

\*These authors contributed equally to this work

#### DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

Except for MS, LR, EC, JR, LL, PH, SL, GG, RB, RX, MV, and UM all other authors are either former or current employees of Pfizer.

**GENE EXPRESSION DATA:** All gene expression information is available at the Gene Expression Omnibus ([www.ncbi.nlm.nih.gov/geo/](http://www.ncbi.nlm.nih.gov/geo/)) under accession number GSE39557.

#### AUTHOR CONTRIBUTION

E.S. M and K.E. H conceived and designed the project. E.S.M., P.J. B., M.J. S., L.G. R, J. Y., E.M. C., J.R., L. L., P. H., S. Y. L., G. G., C. J., J. X., T. X., J.L., S. W., T. V., R.T. B., R.J. X., M.G. V., J. K. U. M., and K.E. H. performed the experiments, analyzed, and interpreted the data. E.S. M, P. J. B, M.J. S, and K.E. H wrote the manuscript.

signatures, including *KRAS* mutant and metastatic CRC. Further analyses revealed enrichment for numerous disease-relevant biological pathways, including glucose metabolism. Functional assessment *in vitro* and *in vivo* validated this finding and highlighted the dependence of *Kras* mutant CRC on oncogenic signaling and on aerobic glycolysis.

**Conclusions**—We have successfully characterized a novel GEMM-derived orthotopic transplant model of human *KRAS* mutant CRC. This approach combines *in vitro* screening capability using low-passage cell lines that recapitulate human CRC and potential for rapid *in vivo* validation using cell line-derived tumors that develop in the colonic microenvironment of immunocompetent animals. Taken together, this platform is a clear advancement in preclinical CRC models for comprehensive drug discovery and validation efforts.

### Keywords

*Kras*; MAPK; PI3K; colorectal cancer; GEMM; orthotopic model

---

## INTRODUCTION

Activating *KRAS* mutations are observed in 40–50% of human colorectal cancer (CRC) and pose a significant therapeutic challenge because of their inherent resistance to anti-epidermal growth factor receptor (EGFR) antibodies, such as cetuximab (Erbix) or panitumumab (Vectibix) (1). Whereas this underscores the urgent need for development of novel therapeutic strategies, the overall success rate for the clinical approval of oncology drugs continues to be less than 10% (2). As the largest failure rates occur when efficacy in human patients is first directly assessed (phase II trials), robust pre-clinical models that faithfully model human disease are critical to maximize the efficiency of the clinical drug development pipeline.

The majority of CRC genetically engineered mouse models (GEMMs) employ germ-line or tissue-wide modification of genes that are critical for CRC carcinogenesis (3). Although these are useful models for hereditary cancer predisposition syndromes, such as Familial Adenomatous Polyposis and Lynch Syndrome, they are poor surrogates for sporadic CRC, which comprises ~80% of all CRC cases (4). Furthermore, the majority of these murine tumors present in the small intestine rather than the colon. To circumvent this problem, we have recently described novel GEMMs for sporadic CRC based on the delivery of adenovirus expressing *cre* recombinase (AdCre) in a restricted fashion to the distal colon of *floxed* mice (5). This is a faithful surrogate for human sporadic CRC, as it is based on stochastic and somatic modification of genes known to be important in human CRC, resulting in colonic tumors that develop in the context of the colonic microenvironment of immunocompetent mice. We have successfully used this model to stratify multiple therapeutic responses according to underlying tumor genotype (5, 6). Whereas this is a powerful approach that recreates human CRC with the utmost fidelity, it is more suitable for hypothesis-driven mechanistic interrogation of specific targeted therapies, rather than large-scale high throughput drug discovery efforts.

To create a high throughput drug discovery-validation platform that closely mimics human CRC, we developed a novel GEMM-derived orthotopic transplant model that combines the capability for traditional *in vitro* high throughput drug screening with rapid *in vivo* validation in the context of a species-matched tumor-stroma microenvironment and an intact immune system. Several high throughput drug screening approaches rely on the use of pre-existing highly passaged human CRC cell lines with poorly defined genetics; in addition, investigators have utilized patient-derived tumorgraft models in which a human tumor fragment is serially passaged in an immunodeficient mouse host in order to study its biological characteristics and response to therapeutics. Here, we have utilized primary tumor

tissue from our GEMMs for sporadic CRC to derive low passage, genetically-defined cell lines, thus providing a platform for rapid *in vitro* drug discovery. Furthermore, to facilitate rapid *in vivo* candidate drug validation, we developed a procedure to engraft these cell lines into the native colonic environment of immunocompetent mice, thus modeling the appropriate tumor-stroma-immune microenvironment for CRC carcinogenesis.

Thus, GEMMs have become a useful system in which to recapitulate and investigate a broad spectrum of human diseases, including cancers which derive from somatic genetic events. As is the case with any model of human disease condition, there are benefits as well as limitations to GEMMs as models of human carcinogenesis. Our GEMMs of CRC have certain advantages over traditional human tumor cell lines in that they are low-passage and clearly genetically defined, as well as over human tumorgrafts, in that they can be studied within the context of a colonic environment with a fully intact immune system. Indeed, there are limitations with any GEMMs of human disease, including the possibility that there may be aspects of human CRC not fully captured within the context of the limited driver mutations we have engineered into these models. In addition, the extent to which these models recapitulate the therapeutic response seen in human CRC patients may also be incomplete. Nonetheless, we feel that a successful preclinical effort must take advantage of all possible models of the human disease condition, and that these GEMMs play a useful role within such a comprehensive effort.

Since *KRAS* mutational status is an independent predictor of treatment response in CRC (1), we generated GEMMs of advanced CRC based on: 1) somatic loss of the tumor suppressors *Apc* and *p53* (AP) and 2) *Apc* and *p53* loss with concomitant gain of an activating *Kras* mutation (AKP). Subsequently, we derived corresponding panels of murine cell lines and demonstrated that they contain many canonical features of human CRC biology. Finally, we successfully engrafted these cell lines into the appropriate colonic microenvironment of immunocompetent mice and observed robust tumor growth and development. Here we present the development, characterization, and validation of our novel discovery-validation platform and highlight its utility by demonstrating: 1) the predisposition of *Kras* mutant tumors and tumor-derived cell lines towards enhanced growth and proliferation; 2) the dependency of *Kras* mutant tumors on oncogenic signaling; 3) the generation of a *Kras* signature which closely resembles several recently published CRC signatures and is enriched for hallmark CRC characteristics; 4) the propensity of *Kras* mutant tumors towards aerobic metabolism; and 5) how this phenotypic difference might be exploited for PET-based diagnoses of *Kras* mutant tumors.

## MATERIALS AND METHODS

### Genetically Engineered Mouse Models (GEMM)

The generation and genotyping of *Apc*<sup>CKO</sup>, *Kras*<sup>LSL-G12D</sup>, and *p53*<sup>flox/flox</sup> genetically engineered mice has been previously described (Supplemental Figure 1 and (5)). To generate compound mutant mice, *Apc*<sup>CKO</sup> and *p53*<sup>flox/flox</sup> mice were crossed to generate *Apc*<sup>CKO</sup> *p53*<sup>flox/flox</sup> (AP) mice and *Apc*<sup>CKO</sup>, *Kras*<sup>LSL-G12D</sup>, and *p53*<sup>flox/flox</sup> mice were crossed to generate *Apc*<sup>CKO</sup>, *Kras*<sup>LSL-G12D</sup>, and *p53*<sup>flox/flox</sup> (AKP) mice.

### Adenoviral Infection of the Colonic Epithelium and Endoscopy

12-week old mice were infected with 10<sup>9</sup> pfu Ad5CMVcre (AdCre) (Gene Transfer Vector Core, University of Iowa) after surgical laparotomy under anesthesia (2% isoflurane), as described (5). Resulting compound genotypes and nomenclature are depicted in Supplemental Figure 1. Mice were followed with biweekly optical colonoscopy for tumor development. The Tumor Size Index (TSI) based on the relative ratio of the cross sectional

areas of the tumor to that of the colonic lumen was derived as described (5, 6). Tumor-bearing mice with TSI > 75 were euthanized, and the colons were removed, opened longitudinally, and rinsed with cold PBS. Tumor fragments were isolated for genomic analysis, histology, and cell line establishment. This research protocol was approved by our attending veterinarian, by the Tufts Medical Center Institutional Animal Care and Use Committee (IACUC), and by the Tufts Medical Institutional Biosafety Committee.

### Derivation of Tumor Cell Lines

Tumor samples were washed in 0.04% sodium hypochlorite followed by multiple PBS-gentamycin washes. Samples were minced and digested in collagenase D/dispase (Roche), collected by centrifugation, and digested further in 0.3% pancreatin (Roche) at 37°C. Digested samples were passed through a 40 µm cell strainer (BD Biosciences), collected by centrifugation, re-suspended in defined culture media (DMEM, 10% FBS, 0.2 ng/ml EGF, 1X Insulin-Transferrin-Selenium (Invitrogen), 2.5 µg/ml gentamycin), and plated on 60 mm<sup>2</sup> collagen IV coated dishes (BD Biosciences). Mutational analysis was confirmed using our genotyping protocol as described in the Supplemental Methods.

Additional detailed methods are available in the Supplement.

## RESULTS

### **Kras<sup>G12D</sup> accelerates carcinogenesis in GEMM models of sporadic CRC**

Colonic tumors were induced through surgical administration of AdCre to generate *Apc<sup>CKO</sup> p53<sup>ΔΔ</sup>* (AP) and *APC<sup>CKO</sup> Kras<sup>G12D</sup> p53<sup>ΔΔ</sup>* (AKP) tumors, respectively (Supplemental Figure S1), and followed by optical colonoscopy (Figure 1A). Whereas initial tumor formation was observed in AP mice by seven weeks after surgical induction, neoplastic lesions were detected in AKP mice in as little as two weeks. Analysis of composite tumor growth curves further confirmed more robust tumor growth in AKP compared to AP mice (Figure 1B). In addition, the rate of histologic progression was accelerated in AKP mice (Figure 1C–D). Collectively, these data suggest that somatically activated oncogenic *Kras<sup>G12D</sup>* promotes tumor progression in the context of an *Apc<sup>CKO</sup> p53<sup>ΔΔ</sup>* genetically permissive background.

### **Kras<sup>G12D</sup> increases MAPK and PI3K/mTOR but has no effect on WNT signaling in colonic tumors**

We have previously demonstrated that introduction of *Kras<sup>G12D</sup>* activates the downstream MAPK pathway in tumors derived from *Apc* mutation (5). To examine if a similar response exists in tumors harboring an additional *p53* mutation, protein analysis was performed by western blot to compare levels of p-MEK and p-ERK in individual AP and AKP tumors. While levels of total MEK and ERK were equivalent, AKP tumors demonstrated elevated levels of p-MEK and p-ERK throughout their progression (Figure 2A). These findings, along with activation of PI3K and mTOR signaling, were confirmed by immunohistochemistry (Figure 2B). Next, we examined nuclear and cytoplasmic levels of β-catenin and found that tumors from both AP and AKP mice demonstrated specific accumulation relative to adjacent normal mucosa, which is indicative of aberrant WNT signaling (Supplemental Figure 2B). Taken together, these data suggest that *Kras<sup>G12D</sup>* activates MAPK and PI3K/mTOR signaling and accelerates tumor progression in the context of colonic tumors with *Apc* and *p53* deficiency.

## AP and AKP tumor-derived cell lines are robust *in vitro* models for CRC

To interrogate *Kras*<sup>G12D</sup> CRC biology in the context of *Apc* and *p53* deficiency, we derived low passage primary cell lines from individual AP and AKP colonic tumors. To verify proper recombination of the genetically engineered alleles, we used PCR to examine both primary tumors and cell lines. As expected, both AP and AKP primary tumors, which are comprised of a heterogeneous mixture of tumor cells, supporting stroma, and immune cells, contain a mixture of both non-recombinant and recombinant alleles. After short-term passage ( $P < 3$ ) *in vitro*, PCR analysis demonstrated uniform loss of the non-recombinant alleles (Figure 3A). This suggests that the epithelial cells harboring genetically modified alleles obtain a growth advantage *in vitro* and that these cells eventually dominate the cultured cell population.

Next, we examined the *in vitro* and *in vivo* growth characteristics of AP and AKP cell lines. Cumulative population doublings (CPDs) demonstrate that AKP cells grow at a faster rate compared to AP cells (~0.5 vs 1.5 PDs per day, Figure 3B). To further characterize *in vitro* growth capabilities, AP and AKP cell lines were grown in spheroid-inducing conditions. Consistent with their ability to grow more rapidly in a monolayer, AKP lines also form larger spheroids as evidenced by microscopy as well as a viability assay (Figure 3C). Finally, we performed subcutaneous injections of AP and AKP cells into nude mice. As indicated in Figure 3D, AKP lines displayed an enhanced ability to grow in an immunocompromised *in vivo* setting compared to AP lines. Taken together, these data demonstrate that the addition of *Kras*<sup>G12D</sup> confers a growth advantage *in vitro* and *in vivo*.

## Mutant *Kras* tumor derived cell lines are dependent on oncogenic signaling

Due to elevated MAPK and PI3K/AKT signaling *in vivo* (Figure 2), we hypothesized that *Kras* mutant tumor derived cell lines would also be highly dependent on oncogenic signaling. First, *Kras* dependency was assessed in AP and AKP cell lines, by examining the effects of two independent hairpins targeting *Kras*. As shown in Figure S5A, AKP cell lines exhibited a marked decrease in cell viability upon *Kras* knockdown using small interfering RNA, while AP cell lines were not significantly affected despite protein knockdown being comparable (Figure S5B). These results indicated that the AKP cell lines tested displayed a greater dependency on *Kras* than AP cell lines, which is consistent with our hypothesis of *Kras* mutant cell lines require oncogenic *Kras* for survival. To interrogate the degree of *Kras*-dependency in AKP cell lines *in vivo*, we performed inducible RNA-interference of *Kras* in established tumors *in vivo*. Following doxycycline administration, pronounced growth inhibition was observed relative to non-induced control tumors (Figure 4A). Following 4 days of doxycycline treatment, we examined tumors from both treated ( $n=3$ ) and untreated ( $n=3$ ) mice by Western blot. Tumors exposed to doxycycline demonstrated robust knockdown of *Kras* and consequently loss of p-ERK, suggesting that AKP tumor growth *in vivo* is reliant on MAPK signaling endowed by oncogenic *Kras* (Figure 4B).

Next we examined the effect of MAPK and PI3K/mTOR inhibition using the pathway selective small molecule inhibitors PD-0325901 and PF-04691502, respectively. Treatment with the MEK inhibitor PD-0325901 revealed significantly greater sensitivity ( $p = 10^{-7}$ , Figure 4C) in *Kras* mutant cells, while treatment with the PI3K/mTOR inhibitor PF-04691502 demonstrated a slightly enhanced sensitivity in *Kras* mutant cells to a lower dose (50 nM,  $p = 0.01$ , Figure 4C). Subsequently, a 3-fold increase in PF-04691502 concentration had a greater impact on cell viability with AKP cells exhibiting greater sensitivity to drug treatment ( $p = 10^{-5}$ , Figure 4C). Treatment using combinations of each drug demonstrated an additive effect in both AKP and AP cells with AKP cells showing a marked decrease in viability when compared to non-*Kras* mutant AP cell lines ( $p = 10^{-6}$ , Figure 4C). As expected, Western blot analysis of cells exposed to individual doses of

PD-0325901 and PF-04691502 demonstrated a robust attenuation of p-MAPK and p-PI3K/AKT signaling, respectively, at 6 hours (not shown) and 24 hours (Figure 4D). A decrease in both effector pathway phosphosignaling was observed in both AKP and AP cells with combinations of PD-0325901 and PF-04691502 after 6 hours of treatment (not shown); however, restoration of both p-AKT<sup>Thr308</sup> and p-AKT<sup>Ser473</sup> occurred only in non-*Kras* mutant AP cells after 24 hours (Figure 4D). In addition, the appearance of the apoptotic marker cleaved PARP arose only in AKP cells following a 24 hour treatment with either PD-0325901 or the combination of PD-0325901 and PF-04691502 (Figure 4D) and is consistent with the decreased viability observed (Figure 4C). These results suggest that an acquired or intrinsic non-*Kras*<sup>G12D</sup> mediated bypass mechanism confers relative resistance in AP cells through the induction of p-AKT. Collectively, these data demonstrate that *Kras* mutant cell line growth and viability is dependent on oncogenic signaling, as well as *Kras* itself.

### Transcriptomic analysis reveals tumor derived cell lines capture relevant signatures of human CRC

To further characterize the extent to which our GEMM models recapitulate human disease, gene expression profiling was performed on cell lines derived from 13 murine colon adenocarcinomas (analysis scheme outlined in Figure 5A). The 500 most significantly varied genes were identified using a two-sample *t*-test (FDR<0.05, 2-fold change) and used for hierarchical unsupervised clustering of three AP and ten AKP cell lines. As indicated in Figure 5B, cell lines clustered into two main groups and in concordance with their respective *Kras* genotypes. Differences in gene expression between AKP vs. AP cell lines was further refined by performing supervised clustering using a composite of published *Kras* gene signatures (*Kras* Sig, see Supplemental Methods). This approach was also able to discriminate successfully between AKP and AP status (Figure 5C).

To determine if differential gene expression among AKP and AP cell lines contains any significant overlap with published comparative murine-human signature gene datasets, pairwise comparisons were made to several CRC-related and *KRAS* signatures (7–9). Briefly, the genes differentially expressed in AKP vs. AP were mapped to human orthologues (renamed AKP vs. AP signature, see Supplemental Table S1) and compared to humanized gene signatures of interest, including a composite *KRAS* signature (9), a CRC metastasis signature (10), and intestinal epithelial signatures (ISC) (11). As indicated in Figure 5D, our list of differentially expressed genes displays significant overlap with several published CRC datasets. Notably, the AKP vs. AP gene set shows a striking overlap with a composite *KRAS* signature dataset (*Kras* Sig, Figure 5C). In addition, a significant overlap was observed between our signature with two ISC signatures (Lgr5<sup>hi</sup> and Ephb2<sup>hi</sup>), a late TA signature, and a CRC signature derived from a murine experimental metastasis model (11).

To determine whether our AKP vs. AP signature was enriched in known disease genesets or pathways, we utilized Ingenuity Pathway Analysis software. The top five biological disease categories are listed in Supplemental Table S2. Top disease categories include cancer and gastrointestinal disease, as well as metabolic disease, which may contribute in part to the altered growth kinetics observed in AKP lines. Collectively, these findings suggest that our model displays many of the transcriptional and pathway characteristics observed in intestinal biology, CRC, and oncogenic *Kras*.

## Oncogenic *Kras* promotes an increase in cellular glucose uptake and lactate production *in vitro* and *in vivo*

To examine potential effects of mutant *Kras* on cellular metabolism, we measured *in vitro* bioenergetic activity in AP and AKP cell lines, using the ratio of oxygen consumption rate (OCR) and extracellular acidification rate (ECAR), as a surrogate metabolic determinant. These analyses indicate that AP and AKP cell lines display a differential metabolic profile. OCR/ECAR ratios from *Kras* mutant cell lines are significantly decreased compared to wild-type counterparts (Supplemental Figure S3B). This is the result of an increased ECAR in AKP compared to AP cell lines (Figure 6A), with OCR remaining relatively similar in the two groups (Supplemental Figure S3A). In addition, AKP cell lines displayed enhanced glucose uptake compared to AP lines (Figure 6B). Taken together, these data indicate that activating *Kras* mutation may affect the metabolic characteristics of these cell lines.

Given this differential metabolic profile *in vitro*, we wished to confirm this finding *in vivo*. To this end, we prepared subcutaneous tumors from AP and AKP cell lines. Upon tumor formation, <sup>18</sup>F-fluorodeoxyglucose (FDG) was administered via tail vein injection and mice were imaged by positron emission tomography (PET). As anticipated, FDG-PET produced an appreciable signal in heart (H), spine (S), and tumor (T). As indicated in Figure 6C, subcutaneous tumors from *Kras* mutant AKP lines produced a significantly higher FDG-PET signal. In addition, both mean and maximum calculated standardized uptake values (SUV) were greater in AKP lines (Supplemental Figures S3C and D). To determine if oncogenic *Kras* contributed to a concomitant increase in lactate production, intra-tumor lactate concentration was measured biochemically. Subcutaneous tumors from *Kras* mutant AKP cell lines had significantly more lactate than those with wild-type *Kras* (Figure 6D), a finding consistent with the Warburg Effect (12). Taken together, this data indicates that oncogenic *Kras* contributes to enhanced glucose uptake and glycolytic metabolism in our model system. In addition, given these findings, we performed a further investigation of our transcriptomic data to assess whether glucose transporters were differentially regulated. Indeed, the glucose transporter SLC2A1 (GLUT-1) is differentially expressed in our *Kras* mutant models, as indicated in Figure S6, further suggesting that alterations in *Kras* may lead to dysregulation of relevant metabolic programs.

## Intrasplenic injection of cell lines results in tumor formation at an orthotopic metastatic site

Given that the common therapeutic approach to treating advanced CRC is to treat the metastatic sites, we sought to determine whether our GEMM tumor cell lines could recapitulate metastatic growth. To this end, we performed intrasplenic injections of two independent AKP cell lines and observed growth in the liver. As indicated in Figure S4, both lines created appreciable tumor masses in the liver, as indicated by gross pathology, H&E staining and PET/CT (Figures S4A, B and C, respectively). Thus, these results demonstrate that our GEMM tumor cell line models can be utilized to test future preclinical therapeutic strategies for treating metastatic lesions.

## Orthotopic transplantation of cell lines into the distal colon results in invasive adenocarcinoma

To create an orthotopic model of invasive adenocarcinoma in an immunocompetent host, we established a method for transplanting cell lines derived from primary colonic tumors into the native colonic environment of a syngeneic immunocompetent recipient host mouse (see Supplemental Methods). A representative endoscopic image of a tumor established from an injection of AKP cells is shown in Figure S2A. Resulting tumors were excised after 5 weeks and sectioned. As indicated in Figure S2B, H&E sections of tumor and adjacent normal tissue indicated that these tumors are poorly differentiated, while immunohistochemical

analysis found that tumor regions contained elevated nuclear  $\beta$ -catenin and phosphorylated constituents of the MAPK pathway compared to adjacent normal tissue, markers of deregulated WNT signaling, and colonic transformation. Furthermore, staining for Ki67 and PECAM (CD31), markers of mitosis and angiogenesis, respectively, indicated an elevated proliferation rate and angiogenic response within tumor areas, as compared to adjacent normal colon tissue (Figure S2B).

## DISCUSSION

Activating *KRAS* mutations are commonly seen in 40–50% of human CRC (13). Whereas the prognostic role of such mutations is controversial, it is evident that they are powerful positive predictors for resistance to treatment with anti-EGFR therapies, such as cetuximab or panitumumab (14, 15). Because of the central role for *KRAS* in EGFR and other receptor tyrosine kinase (RTK) signaling pathways during CRC carcinogenesis (16), robust *KRAS*-specific treatments are desperately needed for effective CRC treatment. As such efforts have been widely unsuccessful to date (17), the development of novel therapeutic approaches for treatment of *KRAS* mutant CRC is a critical unmet clinical need.

Despite the identification of many candidate drug compounds during pre-clinical discovery efforts, the subsequent rate of success through the clinical trial pipeline is abysmal (18). Traditional preclinical drug discovery platforms often rely on genetically undefined and highly passaged human tumor cell lines. The *in vitro* discovery phase is often followed by *in vivo* validation in immunodeficient mice that suffer from complete species mismatch in the tumor microenvironment. This is a significant shortcoming in light of the increasing evidence implicating the critical interplay between the tumor, its supporting stroma, and the surrounding immunological milieu (19). As the highest failure rate occurs during phase II testing when clinical efficacy in humans is first directly tested, preclinical models that are better surrogates for human disease are needed (20). GEMMs possessing conditional alleles that recapitulate mutations known to be important in human disease provide an attractive and powerful alternative, as they recapitulate the full histologic, genomic, transcriptomic, and proteomic spectrum of disease seen in human disease (21, 22). Indeed, numerous successful cancer discovery and validation efforts have been possible through the use of comprehensive comparative oncogenomic and oncoproteomic analyses (22–26). Furthermore, such GEMMs can be used to derive highly successful predictions of eventual therapeutic response in human disease (5, 27). Whereas GEMMs are excellent surrogates for human disease, they are more suited for specific hypothesis-driven efforts rather than high throughput screening. To address this deficiency, we wished to develop a composite platform comprised of 1) high throughput *in vitro* screening based on CRC GEMMs and 2) closely linked *in vivo* validation that faithfully recapitulates human disease.

Many CRC GEMMs utilize germline or tissue-wide modification of genes involved in human carcinogenesis that paradoxically results in a high multiplicity of predominantly small intestinal tumors (28). Whereas GEMM-derived cell lines have been described for models of lung and pancreatic cancer (29), CRC GEMM-derived cell lines have not. This may be because the large tumor burden in most CRC GEMMs results in premature death, thereby precluding the isolation and characterization of distinct tumor material that is amenable to generation of viable cell lines. Here, we have characterized two novel CRC GEMMs that present with a very low multiplicity of large advanced primary colonic tumors, making these an ideal basis for derivation of cell lines to incorporate into our GEMM derived orthotopic model. We used primary colonic tumor tissue from these two GEMMs to successfully generate low passage cell lines that recapitulate many canonical features of human CRC. In addition, low-passage cell lines derived from primary tumors recapitulate this enhanced proliferative phenotype when propagated *in vitro*, as well as in subcutaneous



space *in vivo*. Gene expression signatures generated from these low passage *Kras* mutant cell lines are highly concordant with several signatures associated with *KRAS* mutation, as well as enhanced proliferation, metastasis, and stem-cell signatures, providing evidence for common biology between our model system and CRC. Furthermore, our CRC GEMM expression signatures are highly enriched for biological functions and processes associated with human cancer, gastrointestinal disease, and altered metabolism. Taken together, these findings suggest that the cell lines derived from primary GEMM tumors recapitulate many canonical features of human CRC biology and are a robust foundation for our orthotopic model.

Whereas traditional xenograft models suffer from complete species mismatch in the tumor microenvironment, our strategy permits engraftment into immunocompetent, syngeneic hosts. Multiple approaches to develop orthotopic transplant models in mice have been described, including cecal and colonic injections (30–32). Unfortunately, these strategies employ subepithelial injection of tumor cells into the supporting stroma, which is not the native microenvironment for CRC carcinogenesis. Here, we describe a method in which we disrupt the native colonic epithelium, thereby permitting robust and reproducible cell line engraftment in the colonic epithelial compartment. Further, our model allows for the development and reimplantation of syngeneic tumor cells using any number of genetic combinations. Limitations intrinsic to the model itself may include a lack of genetic heterogeneity due to the finite number of initial driver mutations built into the model, as well as, potential for the tumors themselves to manifest a limited level of intratumoral heterogeneity, as compared to human CRC counterparts. To better recapitulate such heterogeneity, implantation of a mixture of primary cell cultures that derive from independent tumor models could be implemented in the future.

there are limitations intrinsic to the model itself, including a lack of genetic heterogeneity due to the finite number of driver lesions built into the model, as well as potential for the tumors themselves to manifest a limited level of intratumoral heterogeneity compared to human CRC counterparts. Nonetheless, we have developed a platform that allows for the validation of findings from high throughput *in vitro* screens in an *in vivo* setting that recapitulates CRC carcinogenesis in its native environment.

Given the lack of success in generating selective pharmacological against oncogenic *KRAS*, several efforts have attempted to identify potential synthetic lethal targets (33–36). To this end, the *Kras* wild type and mutant models of CRC described and characterized herein will provide future functional screening efforts aimed at identifying and, more critically, validating (37, 38) such synthetic lethal targets in *KRAS* mutant CRC. In addition, the ability to transplant these low passage cell lines back into the relevant colonic microenvironment and reconstitute a colorectal tumor will provide an invaluable platform for future functional screening efforts to identify putative therapeutic targets using RNAi or genetically engineered gain-of-function approaches. Furthermore, we have demonstrated the feasibility of asking sophisticated hypothesis-driven gain-of-function and loss-of-function questions using relatively simple *in vitro* genetic manipulations that can be rapidly validated *in vivo*. In this manner, we can circumvent some of the limitations of traditional CRC GEMMs that require laborious targeting of embryonic stem cells and/or cumbersome mouse breeding.

Activation of oncogenes and/or loss of tumor suppressor genes such as *KRAS* (39), *MYC* (40), and *TP53* (41) increase glucose uptake and lactate production. These observations are consistent with the ‘Warburg effect’ that stipulates that tumor cells rely mainly on aerobic glycolysis to generate ATP instead of the metabolically more efficient mitochondrial oxidative phosphorylation (12). Therefore, mutations in diverse oncogenic pathways may affect glucose utilization by tumor cells. Consequently, FDG-PET has been employed as a

diagnostic tool to detect metabolically active foci, which are representative of cancer cell dissemination in the clinical setting (42). Given the prevalence of metabolic pathway enrichment in our transcriptome analysis, we wished to determine whether the activation of oncogenic *Kras* enhanced metabolic activity in our model system. In support of an altered metabolic state, our functional analyses found that *Kras* mutant cell lines demonstrate decreased *in vitro* OCR/ECAR ratios, increased *in vitro* and *in vivo* FDG-PET signal, and increased *in vivo* lactate production. These findings are consistent with a metabolic shift towards increased aerobic glycolysis, termed the Warburg effect (43), and are concordant with recent findings implicating a role for oncogenic *KRAS* in a shift toward increased glycolysis and glucose consumption (44). This shift in metabolism is thought to provide cancer cells with a growth advantage in the tumor microenvironment, (45), and it has been suggested that aerobic glycolysis can contribute to malignant transformation (46). Furthermore, this finding highlights the potential of FDG-PET for non-invasive discrimination between *KRAS* mutant and non-mutant CRC metastases. Thus, our *Kras* mutant GEMM model presents with several phenotypes of *KRAS* mutant CRC, including enhanced proliferation, heightened signaling through MAPK and PI3K pathways, and an increased propensity towards aerobic metabolism.

In conclusion, we present here the establishment of two genetically defined models of sporadic CRC biology, including one that displays several hallmark traits of *KRAS* driven CRC.

These findings provide evidence that this model system faithfully recapitulates human CRC, thereby making it a highly desirable platform for preclinical therapeutic target identification for *KRAS* CRC and subsequent *in vivo* validation.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

We would like to thank Dr. Sabine Tejpar for critical review of this manuscript.

## References


1. Prenen H, Tejpar S, Van Cutsem E. New strategies for treatment of *KRAS* mutant metastatic colorectal cancer. *Clin Cancer Res*. 2010; 16:2921–6. [PubMed: 20460490]
2. DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. *Clin Pharmacol Ther*. 2010; 87:272–7. [PubMed: 20130567]
3. Taketo MM, Edelmann W. Mouse models of colon cancer. *Gastroenterology*. 2009; 136:780–98. [PubMed: 19263594]
4. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. *N Engl J Med*. 2009; 361:2449–60. [PubMed: 20018966]
5. Hung KE, Maricevich MA, Richard LG, Chen WY, Richardson MP, Kunin A, et al. Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. *Proc Natl Acad Sci U S A*. 2010; 107:1565–70. [PubMed: 20080688]
6. Roper J, Richardson MP, Wang WV, Richard LG, Chen W, Coffee EM, et al. The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of *PIK3CA* wild-type colorectal cancer. *PLoS One*. 2011; 6:e25132. [PubMed: 21966435]
7. Arena S, Isella C, Martini M, de Marco A, Medico E, Bardelli A. Knock-in of oncogenic *Kras* does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers. *Cancer Res*. 2007; 67:8468–76. [PubMed: 17875685]

8. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. *Nature*. 2006; 439:353–7. [PubMed: 16273092]
9. Sweet-Cordero A, Mukherjee S, Subramanian A, You H, Roix JJ, Ladd-Acosta C, et al. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. *Nat Genet*. 2005; 37:48–55. [PubMed: 15608639]
10. Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. *Gastroenterology*. 2010; 138:958–68. [PubMed: 19914252]
11. Merlos-Suarez A, Barriga FM, Jung P, Iglesias M, Cespedes MV, Rossell D, et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. *Cell Stem Cell*. 2011; 8:511–24. [PubMed: 21419747]
12. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science*. 2009; 324:1029–33. [PubMed: 19460998]
13. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, et al. Prevalence of ras gene mutations in human colorectal cancers. *Nature*. 1987; 327:293–7. [PubMed: 3587348]
14. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. *J Clin Oncol*. 2008; 26:1626–34. [PubMed: 18316791]
15. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. *Cancer Res*. 2006; 66:3992–5. [PubMed: 16618717]
16. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. *Lancet Oncol*. 2011; 12:594–603. [PubMed: 21163703]
17. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. *J Natl Cancer Inst*. 2009; 101:1308–24. [PubMed: 19738166]
18. Ledford H. Translational research: 4 ways to fix the clinical trial. *Nature*. 2011; 477:526–8. [PubMed: 21956311]
19. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011; 144:646–74. [PubMed: 21376230]
20. Arrowsmith J. Trial watch: Phase II failures: 2008–2010. *Nat Rev Drug Discov*. 2011; 10:328–9. [PubMed: 21532551]
21. Frese KK, Tuveson DA. Maximizing mouse cancer models. *Nat Rev Cancer*. 2007; 7:645–58. [PubMed: 17687385]
22. Maser RS, Choudhury B, Campbell PJ, Feng B, Wong KK, Protopopov A, et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. *Nature*. 2007; 447:966–71. [PubMed: 17515920]
23. Carretero J, Shimamura T, Rikova K, Jackson AL, Wilkerson MD, Borgman CL, et al. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. *Cancer Cell*. 2010; 17:547–59. [PubMed: 20541700]
24. Faca V, Krasnoselsky A, Hanash S. Innovative proteomic approaches for cancer biomarker discovery. *Biotechniques*. 2007; 43:279, 81–3, 85. [PubMed: 17907570]
25. Hung KE, Faca V, Song K, Sarracino DA, Richard LG, Krastins B, et al. Comprehensive proteome analysis of an Apc mouse model uncovers proteins associated with intestinal tumorigenesis. *Cancer Prev Res (Phila)*. 2009; 2:224–33. [PubMed: 19240248]
26. Martin ES, Tonon G, Sinha R, Xiao Y, Feng B, Kimmelman AC, et al. Common and distinct genomic events in sporadic colorectal cancer and diverse cancer types. *Cancer Res*. 2007; 67:10736–43. [PubMed: 18006816]
27. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. *Nat Med*. 2008; 14:1351–6. [PubMed: 19029981]


28. Uronis JM, Threadgill DW. Murine models of colorectal cancer. *Mamm Genome*. 2009; 20:261–8. [PubMed: 19444507]
29. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. *Nat Med*. 2011; 17:500–3. [PubMed: 21460848]
30. Fu XY, Besterman JM, Monosov A, Hoffman RM. Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. *Proc Natl Acad Sci U S A*. 1991; 88:9345–9. [PubMed: 1924398]
31. Tseng W, Leong X, Engleman E. Orthotopic mouse model of colorectal cancer. *J Vis Exp*. 2007:484. [PubMed: 18989400]
32. Zigmund E, Halpern Z, Elinav E, Brazowski E, Jung S, Varol C. Utilization of murine colonoscopy for orthotopic implantation of colorectal cancer. *PLoS One*. 2011; 6:e28858. [PubMed: 22174916]
33. Babij C, Zhang Y, Kurzeja RJ, Munzli A, Shehabeldin A, Fernando M, et al. STK33 kinase activity is nonessential in KRAS-dependent cancer cells. *Cancer Res*. 2011; 71:5818–26. [PubMed: 21742770]
34. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. *Nature*. 2009; 462:108–12. [PubMed: 19847166]
35. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. *Cell*. 2009; 137:835–48. [PubMed: 19490893]
36. Vicent S, Chen R, Sayles LC, Lin C, Walker RG, Gillespie AK, et al. Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. *J Clin Invest*. 2010; 120:3940–52. [PubMed: 20972333]
37. Naik G. Scientists' Elusive Goal: Reproducing Study Results. *Wall Street Journal*. Dec 02.2011 2011 [cited; Available from: <http://online.wsj.com/article/SB10001424052970203764804577059841672541590.html>].
38. Chan DA, Giaccia AJ. Harnessing synthetic lethal interactions in anticancer drug discovery. *Nat Rev Drug Discov*. 2011; 10:351–64. [PubMed: 21532565]
39. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. *Science*. 1987; 235:1492–5. [PubMed: 3103217]
40. Fan Y, Dickman KG, Zong WX. Akt and c-Myc differentially activate cellular metabolic programs and prime cells to bioenergetic inhibition. *J Biol Chem*. 2010; 285:7324–33. [PubMed: 20018866]
41. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, et al. p53 regulates mitochondrial respiration. *Science*. 2006; 312:1650–3. [PubMed: 16728594]
42. Som P, Atkins HL, Bandoypadhyay D, Fowler JS, MacGregor RR, Matsui K, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. *J Nucl Med*. 1980; 21:670–5. [PubMed: 7391842]
43. Warburg O. On the origin of cancer cells. *Science*. 1956; 123:309–14. [PubMed: 13298683]
44. Neuzil J, Rohlena J, Dong LF. K-Ras and mitochondria: Dangerous liaisons. *Cell Res*. 2011
45. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? *Nat Rev Cancer*. 2004; 4:891–9. [PubMed: 15516961]
46. Kondoh H, Lleonart ME, Gil J, Wang J, Degan P, Peters G, et al. Glycolytic enzymes can modulate cellular life span. *Cancer Res*. 2005; 65:177–85. [PubMed: 15665293]

### TRANSLATIONAL RELEVANCE


Treatment of colorectal cancer (CRC) with activating *KRAS* mutations represents a critical unmet clinical need. To evaluate the efficacy of experimental therapeutics in *KRAS* mutant CRC, we previously developed novel genetically engineered mouse models (GEMMs) for *Kras* mutant and non-mutant sporadic CRC. To facilitate high throughput screening, we have generated low passage cell lines derived from our GEMM primary colonic tumors under defined conditions. *Kras* mutant and non-mutant tumor-derived cell lines demonstrated phenotypic differences in tumor growth, dependency on oncogenic signaling, and metabolism. Transcriptomic analysis revealed close intersection with human *KRAS* CRC biology. Furthermore, we developed an innovative approach to transplant our cell lines into the native colonic microenvironment of immunocompetent mice, resulting in rapid, reproducible, and tractable tumor formation. Taken together, these features provide a complementary platform for large-scale and comprehensive drug discovery efforts.



**Figure 1. Heterozygous *Kras*<sup>G12D</sup> in AKP GEMM strains accelerates tumor formation**  
 A) Representative endoscopic images of AP and AKP tumors taken every 2 to 3 weeks. B) Growth curves measured from endoscopy show that the AKP strains develop at a faster rate by ~8x than AP at 10 weeks. C) Resulting primary tumors range from adenomas to carcinomas to invasive carcinomas (representative images of each are shown). D) Frequency of tumor development after AdCre injection.



**Figure 2. Elevated levels of MAPK, PI3K and mTOR signaling in tumors from AKP strain**  
 A) Western blots for MAPK proteins using dissected tumor lysates from AP and AKP strains. Phospho- (pMek<sup>Ser221</sup> and p-Erk<sup>Thr220/Tyr204</sup>) levels of MAPK signaling are elevated in AKP, while total (Mek and Erk) levels are unchanged. B) Immunohistochemical staining in AP and AKP tumor sections. In AKP strains, elevated levels of MAPK (p-Mek<sup>Ser221</sup> and pErk<sup>Thr220/Tyr204</sup>), PI3K (p-Akt<sup>Ser473</sup>), mTORc (p-S6<sup>Ser240/244</sup>), and WNT (β-catenin) signaling are observed.




**Figure 3. Generation of colon epithelial tumor cell lines from AP and AKP GEMM models and characterization of growth kinetics**


A) Deletion of APC, *Kras* and p53 in cell lines from AP and AKP. PCR genotyping confirms that tail contains non-recombined *Apc* (*flox*= 430 bp), *Kras* (*LSL* = 500 bp) and p53 (*flox* = 370 bp) alleles, and cell lines only recombined *Apc* (*CKO* = 500 bp), *Kras* ( $\Delta$ *LSL* = 700 bp) and p53 ( $\Delta$  = 612 bp) alleles. Tumor samples at the time of dissection contain epithelial cells and other cell types, consequently, the *floxed Apc*, *Kras* and *p53* alleles are present as well as the *Cre*-recombined alleles. B) Cumulative population doublings (CPDs) in AP and AKP cell lines. AKP lines display a greater rate of doubling compared to AP lines. C) Spheroid growth assay in AP and AKP cell lines on low adhesion nanoculture plates. AKP lines form larger spheroids and enhanced viability over time as evidenced by Cell Titer Glo (CTG). D) In vivo tumor growth in AP, AKP cell lines. Cell lines were



transplanted into nude mice subcutaneously and tumor volume was measured over time. AKP lines display an increased rate of *in vivo* growth compared to AP lines.




**Figure 4. AKP cell lines are dependent on oncogenic MAPK and PI3K/AKT signaling**  
**A)** *In vivo* tumor growth inhibition of AKP tumor derived cell lines by doxycycline (dox) inducible *Kras* knockdown. **B)** Representative western blot analysis of established subcutaneous tumors following mock or dox treatment. Tumors were harvested 4 days post-induction of shRNA. **C)** Western blot analysis of the MAPK and PI3K/AKT pathways following single or combination treatment with the pathway selective inhibitors PD-325901 and PF-04691502. AKP and AP cells were treated with control, 50 nM PD-325901, 50 or 150 nM PF-04691502, or combinations for 72 hours, and cell viability was assessed. **D)** Western blot analysis of AKP and AP cells treated with control, 50 nM PD-325901, 50 or 150 nM PF-04691502, or combinations for 24 hours.



**Figure 5. Gene expression analysis of AP and AKP cell lines**

A) Workflow of genomic analysis performed on AP and AKP cell lines. B) Unsupervised clustering results based on the 500 most varied genes from 3 AP and 10 AKP cell lines. Log<sub>2</sub> transformed data was further adjusted by means and then clustered. Cell lines clearly cluster based on genotype. C) Supervised clustering was performed on the 3 AP and 10 AKP cell lines, using an independent *Kras* signature gene list (*Kras* Sig, see methods). A total of 544 differentially expressed genes were used in this clustering (see methods). Log<sub>2</sub> transformed data was adjusted and clustered as in B. Again, cell lines cluster based on genotype. D) Pairwise comparisons using the AKP vs. AP signature and published CRC signatures. A detailed description of each signature is provided in the Supplemental Methods.



**Figure 6. Assessment of *in vivo* glucose uptake and lactate production in subcutaneous tumors**  
 A) *In vitro* measurement of extracellular acidification rate (ECAR) in AP and AKP cell lines. B) *In vitro* glucose uptake in AP and AKP cell lines. C) Subcutaneous tumors imaged by positron emission tomography (PET) following injection of <sup>18</sup>F-FDG. Regions of enhanced signal include heart (H), spine (S), and tumor (T). Tumors from AKP cell lines (*Kras* mutant) display a greater signal than those from AP cell lines (*Kras* wildtype). D) AKP tumors display elevated lactate metabolite abundance.